Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 RECEIVED SECRETARY OF THE SENATE PUBLIC RECORDS

05 AUG 17 AM 11: 06

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name King & Spalding LLP		
	than previously reported	
1700 Pennsylvania Avenue, N.W. 3. Principal Place of Business (if different from line 2) City: Washington	State/Zip (or Country): D.C.	20006
4. Contact Name Theodore M. Hester	Telephone 202-626-2901	5. Senate ID# 21632-330
7. Client Name □ Self UCB Pharma, Inc.		6. House 11)# 30750029

TYPE OF REPORT 8. Year 2005 Midyear (January 1- June 30) X OR Year End (July 1 - Decer

9. Check if this filing amends a previously filed version of this report \Box

10. Check if this is a Termination Report \Box Termination Date

11. No Lobbying Activ

INCOME OR EXPENSE - Complete Either Line 12 OR Line 13

	12. Lobbying Firms		13. Organizations
INCOME rel period was:	ating to lobbying activities for this reporting	EXPENSE reperiod were:	elating to lobbying activities for this reporting
Less than \$10,	000	Less than \$10	000 🗆
\$10,000 or mo	ore 5 \$ <u>60,000</u> Income (nearest \$20,000)	\$10,000 or m	ore D \$ Expenses (nearest \$20,0
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the			TNG METHOD. Check box to indicate exp thod. See instructions for description of opt
registrant by any other entity for lobbying activities on behalf of the client).	D Method A.	Reporting amounts using LDA defiritions	
		I Method B.	Reporting amounts under section 6033(b)(Internal Revenue Code
9		D Method C.	Reporting amounts under section 162(e) of Internal Revenue Code
0 0 0		L <u>.</u>	
💭 Signature –			

C Printed Name and Title _____

LD-2 (REV. 6/98)

Page <u>1</u>

Registrant Name King & Spalding LLP

Client Name <u>UCB Pharma, Inc.</u>

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the 1 engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code <u>HCR (one per page)</u>

16. Specific lobbying issues

Pharmaceutical issues, including implementation of Medicare Prescription Drug benefit and e treatment.

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. House of Representatives U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
William C. Talmadge	
Allison Kassir	
	·

19. Interest of each foreign entity in the specific issues listed on line 16 above \Box Check if None

The foreign entity has an interest in pharmaceutical issues, in implementation of the Medicare Prescr. benefit, and in epilepsy treatment.

nth	Date: <u>August 9, 2005</u>
Theodore M. Hester, Partne	<u>r</u>
	Theodore M. Hester, Partne

LD-2 (REV. 6/98)